Promus PREMIER™

Everolimus-Eluting Platinum Chromium Coronary Stent System

PLATINUM Long Lesion Trial

Platinum Chromium Everolimus-Eluting Clinical Experience

Study Objective: Evaluate the safety and effectiveness of the Promus PtCr EES Stent System1 for the treatment of patients with a de novo lesion > 24 and ≤ 34 mm in length; ≥ 2.50 mm to ≤ 4.25 mm in diameter.
Study Design: Prospective, Single-arm, Multicenter.

0% ARC ST (Def/Prob) and 0% TV-MI

PLATINUM Long Lesion Trial

2-Year Results2

0% ARC ST (Def/Prob) and 0% TV-MI

4.8% TV-MI

SPIRIT PRIME Long Lesion Registry

2-Year Results in Perspective3,4

4.8% TV-MI

PREMIER Architecture.
PREMIER Outcomes.


Features the only customized Platinum Chromium Stent architecture, the market-leading Everolimus drug and PVDF-HFP polymer combination and an enhanced catheter to provide Premier outcomes.

Top